- •MINOCA is 6-fold more frequent in Fabry Disease vs Hypertrophic Cardiomyopathy.
- •MINOCA may be considered a red flag for Fabry Disease.
- •In Fabry Disease, MINOCA is associated to a more advanced stage of cardiomyopathy.
Abbreviations:CMD (coronary microvascular dysfunction), FD (Fabry disease), HCM (Hypertrophic Cardiomyopathy), LVEF (left ventricular ejection fraction), LVH (left ventricle hypertrophy), LVWT (left ventricular wall thickness), MINOCA (Myocardial infarction with non-obstructive coronary arteries)
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Fourth universal definition of myocardial infarction (2018).Eur. Heart J. 2019; 40: 237-269
- ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.Eur. Heart J. 2017; 38: 143-153
- The evolving role of cardiac imaging in patients with myocardial infarction and non-obstructive coronary arteries.Prog. Cardiovasc. Dis. 2021 Sep-Oct; 68: 78-87
- American Heart Association interventional cardiovascular Care Committee of the Council on clinical cardiology; council on cardiovascular and stroke nursing; council on epidemiology and prevention; and council on quality of care and outcomes research. Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease: a scientific statement from the American Heart Association.Circulation. 2019 Apr 30; 139: e891-e908
- Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease.Int. J. Cardiol. 2018 Jun 15; 261: 18-23
- Characteristics of patients presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA) in Poland: data from the ORPKI national registry.J. Thromb. Thrombolysis. 2019 Apr; 47: 462-466
- Coronary microvascular dysfunction in patients with cardiomyopathies.Circ. Heart Fail. 2008; 1: 150-152
- Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson-Fabry disease.Eur. J. Heart Fail. 2013 Dec; 15: 1363-1373
- Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.N. Engl. J. Med. 2003; 349: 1027-1035
- Massive coronary microvascular dysfunction in severe Anderson-Fabry disease cardiomyopathy.Circ. Cardiovasc. Imaging. 2019 Jun; 12e009104
- 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines.Circulation. 2020 Dec 22; 142: e558-e631
- Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Orphanet J. Rare Dis. 2015 Mar 27; 10: 36
- Standard ECG for differential diagnosis between Anderson-Fabry disease and hypertrophic cardiomyopathy.Heart. 2022 Jan; 108: 54-60
- The coronary circulation and blood flow in left ventricular hypertrophy.J. Mol. Cell. Cardiol. 2012 Apr; 52 (Epub 2011 Sep 5): 857-864https://doi.org/10.1016/j.yjmcc.2011.08.028
- Angina in Fabry disease reflects coronary small vessel disease.Circ. Heart Fail. 2008 Sep; 1: 161-169
- Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy.Circulation. 2014 Oct 21; 130: 1530-1531
- High incidence of thrombosis in Fabry’s disease.Intern. Med. 1997 May; 36: 327-329https://doi.org/10.2169/internalmedicine.36.327